Skip to main content
. Author manuscript; available in PMC: 2011 Mar 30.
Published in final edited form as: Oncogene. 2010 Jul 19;29(39):5359–5369. doi: 10.1038/onc.2010.274

Fig. 5. Jak2 deficiency leads to lack of Stat5 activation but not expression of ERα and Cyclin D1.

Fig. 5

(a) Immunohistochemistry to assess the PRL-mediated activation of Stat5 in control tumors and cancers lacking Jak2. Insets show the PRL-induced activation of Stat5 in normal #3 mammary glands derived from the tumor-bearing, wildtype recipient females. (b) Immunohistochemistry to determine the continuous expression of ERα and Cyclin D1 (Ccnd1) in PRL-induced mammary cancers that lack Jak2 and their wildtype controls. All slides were counterstained with hematoxylin (bars, 50 μm).